Skip to content
DataLookout
Menu

NCT06981390

Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria shortened, about 5 words
    • Site details revised
  2. Notable Primary completion date: Feb 20, 2026 to Feb 20, 2027v3 Show 4 more changesShow less
    • Start date: Feb 1, 2025 to May 1, 2026
    • Trial status: Recruiting to Not Yet Recruiting
    • Study completion date: Mar 20, 2026 to Mar 20, 2027
    • Site details revised
  3. Notable Phase: Phase 1 to Not applicablev2 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary completion date: Oct 20, 2026 to Feb 20, 2026
    • Study completion date: Dec 20, 2026 to Mar 20, 2026
    • Start date changed from estimate of Jun 1, 2025 to Feb 1, 2025
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Saphenous Vein Graft (SVG) Patency at 12 Months
Timeframe: 12 months post-CABG

Secondary (3)

Bleeding Events
MACCE episodes
All-Cause Mortality

Arms and interventions

3-Month DAPT GroupActive comparator

Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 3 months, followed by aspirin monotherapy

6-Month DAPT GroupActive comparator

Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 6 months, followed by aspirin monotherapy

12-Month DAPT GroupExperimental

Ticagrelor (90 mg BID) + Aspirin (100 mg QD) for 12 months, followed by aspirin monotherapy

Drugs: Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy)

Sites

1 site in 1 country

  • the Second Hospital of Jilin UniversityChangchun, Jilin, China